Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 4/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 3/20 | 0.50 |
| ▸ | CDH1 | P12830 | 1/20 | 0.50 |
| ▸ | APC | P25054 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.48 |
| ▸ | RXRB | P28702 | 1/20 | 0.48 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9943861 | 0.94 | TSHR (0.58) | TSHRALOX15KDM4ESRD5A2SRD5A1 | |
| SCHEMBL18758 | 0.86 | KDM4E (0.68) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| SCHEMBL29359975 | 0.86 | KDM4E (0.68) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| SCHEMBL29594563 | 0.86 | KDM4E (0.68) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| SCHEMBL6916181 | 0.86 | KDM4E (0.68) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| Terephthalic Acid SCHEMBL2846917 | 0.84 | TSHR (0.67) | TSHRALOX15KDM4ESRD5A2MEN1 | |
| SCHEMBL6666460 | 0.84 | KDM4E (0.65) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| Potassium SCHEMBL9719670 | 0.84 | KDM4E (0.65) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| Bromide SCHEMBL8758652 | 0.84 | KDM4E (0.65) | TSHRKDM4ESRD5A2MEN1KMT2A | |
| SCHEMBL20942846 | 0.84 | KDM4E (0.65) | TSHRKDM4ESRD5A2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 174 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1667647-A4 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | claimed |
| EP-1667647-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-06-14 | — | — | EP | claimed |
| WO-2005032468-A2 | MONOCYCLIC AND BICYCLIC LACTAMS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-14 | — | — | WO | claimed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | claimed |
| CN-117658992-A | Benzimidazole compound, preparation method and pharmaceutical application thereof | 中国医学科学院药物研究所 | 2024-03-08 | — | — | CN | disclosed |
| WO-2024001839-A1 | HETEROAROMATIC RING COMPOUND, METHOD FOR PREPARING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| CN-117126152-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117126151-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-117069712-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069713-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117024420-A | Glycolate oxidase inhibitors for use in the treatment of disease | 生物马林药物股份有限公司 | 2023-11-10 | — | — | CN | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| CN-1438993-A | Ethylenediamine derivatives | DAIICHI SEIYAKU CO (JP) | 2003-08-27 | — | — | CN | disclosed |
| CN-1390206-A | Inhibitors of factor Xa | COR THERAPEUTICS INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
| EP-1216231-A2 | INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019798-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-4107329-A | Fluorinated compounds as therapeutics | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | TSHR 2918/4885ALOX15 828/4885KDM4E 3940/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | TSHR 2279/4885ALOX15 4212/4885KDM4E 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.